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INTRODUCTION  
In recent years, biological control of drug delivery has 
been of interest to achieve improved drug 
therapies
1
.Pulsatile drug delivery system has the 
advantageof avoiding drug tolerance
2-4
. The oral pulsatile 
release system was mainly for the treatment of disease 
symptoms such as hypertension, asthma, ischemic heart 
disease and rheumatoid arthritis, that exhibit circadian 
rhythms. The required amount of drug should be released 
from the drug delivery system at the required time of night 
or early morning. The object of the recent study was to 
develop newPulsatile release tablets of time-controlled or 
„site specific‟ drug delivery5-8.  
Atenolol, a β-blocker, is prescribed widely in diverse 
cardiovascular diseases, eg. Hypertension, angina pectoris 
and arrhythmias. The drug is also indicated in prophylactic 
treatment of migraine. Administration of conventional 
tablet has been reported to exhibit fluctuation in the plasma 
drug level, resulting either in manifestation of side effect 
or reduction in drug concentration at the receptor site. 
Atenolol has half life of 6 to 7 hrs. & oral bioavailability is 
50%. It get metabolised through hepatic metabolism & 
does not pass through first pass metabolism.Taking in 
consideration these parameters Atenolol is good candidate 
to administer through pulsatile system. 
Chronobiologically, hypertension peak isin the 
morningabout 5 to7 AM. Sopatients have to take 
conventional tablet at 2 or 3 PM which is non compliance 
to patients. In pulsatile drug delivery, tablets are prepared 
in such manner that they release drug immediately after a 
predetermined lag time. So it is the most popular system 
which deliver drug in time dependent manner and most 
importantlysuitable drug regimen for patientssuffering 
from cardiac disorders.Pulsatile tablet of antihypertensive 
drug should be taken after dinner so that it get released 
after a 5 to 6 hrs of lag time so it is available during 
morning session when there are chances of hypertension 
peak
9-12
. 
In the present study Lubritab, Dicalcium Phosphate 
andPolyox WSR301, in the form of compression coat 
applied over optimizedcore tablets of drug-cyclodextrin 
complex, andwere evaluated as a carrier for time 
dependent drug delivery. This presscoating prevent 
disintegration of core tablet containing Atenolol in gastric 
fluid. On reaching insmall intestine, the tablet will release 
drug after predetermined time, but the water 
solublehydrogel polymer i.e. Polyox WSR301 swell to 
create a lag phase that equal the small intestinal 
transittime. The proposed device can be manufactured 
using currently available pharmaceuticaltechnology and 
materials recognized as safe. 
MATERIAL AND METHOD: 
Material: 
Atenolol was obtained as a gift sample from IPCA. Spray 
dried lactose, Lubritab& all otherchemicals and reagents 
used were either of analytical orpharmaceutical 
gradespurchased from local market. 
Tablet Manufacturing Method: 
Drug Excipients Compatibility Study  
Sample of pure drug, coating, physical mixture of coating 
material and drug in (1 : 1) ratio was placed at accelerated 
stability condition 40±2 °C and 75±5% relative humidity 
for a period of 3 month. At the end of 3 month samples 
were evaluated for drug–excipients compatibility using 
Differential scanning colorimeter (DSC) (Mettler Toledo 
DSC 822e, Japan) and Fourier transformed infrared 
spectroscopy (FT-IR) (Shimadzu Corporation, Japan, 
8400s).  
Solubility enhancement:     
Atenolol is slightly soluble in water &have low 
bioavailability so increasing solubility & bioavailability is 
important for faster dissolution core tablets. For that drug 
& β cyclodextrine complex were prepared in different 
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molar concentrations & selected by theirhighest absorption 
through UV method. Then selected molar concentration 
used to prepare drug-cyclodextrine complex by Freeze 
drying techniquer. 
Formulation of Immediate release core tablets: 
The inner core tablets were prepared by using direct 
compression method. As shown in Table 1 powder 
mixtures of drug , diluents and super disintergrants were 
dry blended for 20 min. followed by addition of 
Magnesium Stearate. The mixtures were then further 
blended for 10 min., 100 mg of resultant powder blend was 
compressed using rotary tabletting machine with a 6mm 
punch and die to obtain the core tablet. 
Coating of core tablets 
Powder blend for press-coated tablet was prepared by dry 
blending together differentcompositions of the Lubritab, 
Polyox WSR301, Xanthum gum and Dicalcium Phosphate. 
These excipients were dry blended in different weight 
compositions using 2
3
 factorial designin order to get 
suitable polymer composition. This composition is dry 
blended until uniformly blended mixture is obtained. This 
mixture is then used for the preparation of press – coated 
tablet using direct compression method (10mm punch). 
2
3
 Full Factorial Design 
A 2
3
 randomized full factorial design was used in this 
study. In this design 3 factors were evaluated, each at 2 
levels, and experimental trials were performed at all 8 
possible combinations. The ratio of Polyox WSR301: 
Lubritab (X1) and Amount ofXanthan Gum (X2) & 
presence of Dicalcium Phosphate (X3)in Coating layer 
were selected as independent variables. The times required 
for maintaining lag time (Y) was selected as dependent 
variable. The experimental design with corresponding 
formulation outline in Table no. 2. 
 
Table 1: Composition of core tablet 
 
Table 2: Design and composition of compression coating Layer 
Batch code X1 X2 X3 
F1 -1  1  1 
F2 -1 -1  1 
F3 -1 -1 -1 
F4  1 -1 -1 
F5  1 -1  1 
F6  1  1 -1 
F7  1  1  1 
F8 -1  1 -1 
 
Evaluation of core and press – coated tablet 
Thickness:  
Thickness of tablets was determined using Vernier caliper. Five tablets from batch wereused, and average values were 
calculated
13-14
. 
Average Weight:  
To determine average weight, each tablet from formulation was weighed using an electronicbalance (AUX-220, 
Shimadzu)
13-14
. 
Hardness:  
The hardness was tested using Monsanto tester. The force is measured in kilograms
13-14
. 
                                                          
1 SSG-sodium starch glycolate,CP- crospovidone, CCS- cross carmellose sodium,SDL- spray dried lactose and SDML- spray dried  
ocimumbasilicum mucilage on lactose as carrier.  
 F1 F2 F3 F4 F5 F6 F7 F8 
DC(mg) 50 50 50 50 50 50 50 50 
SDL(mg) 44 44 44 - - - 50 - 
SDML(mg) - - - 44 44 44 - 50 
CCS(mg) 6 - - 6 - - - - 
CP(mg) - 6 - - 6 - - - 
SSG(mg) - - 6 - - 6 - -
1
 
Independent variables 
Levels X1 (Ratio of Polyox 
WSR301:Lubritab) mg 
X2 (Amount of Xanthan Gum) 
mg 
X3 (Presence of Dicalcium Phosphate) mg 
-1 50:100 50 Without 
 1 125:75 100 With (50) 
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Friability: 
 
For each formulation, the friability of 6 tablets was 
determined using the Roche friabilator(Lab Hosp.)
13-14
. 
In vitro drug release study of press – coated tablets 
In-vitro dissolution studies were performed on the press-
coated tablets prepared by directcompression method using 
0.1N HCL for 2 hrs& 6.8 ph phosphate buffer in USP 
apparatus II with the paddle speed of 50 rpm. Then 1 ml of 
filteredaliquot was withdrawn at pre-samples wereanalysed 
at 225 nm using a UV spectrophotometer. The lag time and 
percentage releasewas determined for the each 
formulation
13-14
. 
RESULT & DISCUSSION : 
Solubility enhancement : 
Atenolol belongs to a group of beta blocker (selective β1 
antagonist) used as antihypertensive, antianginal  and 
antiarrythmic.  Due to its slightly solubility in water, low 
bioavailability (50%) makes it suitable candidate for 
increase its solubility. 
Solubility of Atenolol was enhanced by complexation with 
βcyclodextrine. It was done by different molar ratioswhich 
were stirred saturated solutions for 5-6 hrs, then filtered & 
UV reading taken. By this 1:1 ratio was selected which 
gives highest absorption 0.130 and solubility0.03505 
mg/ml at 225 nm. 
By this complexation solubility of drug increased in HCL 
& 6.8 phosphate buffer. But it was more soluble in 
phosphate buffer shown in table 3. 
 
Table 3: Solubility study 
Materials/Solubility in HCL(mg/ml) 6.8 Phosphate Buffer(mg/ml) 
Drug 0.01964736 0.026 
Drug:Cyclodextrine 0.03652 0.04836 
 
Compatability study 
Drug-Excipient Interactions: 
The IR spectra of Formulation were compared with the 
standard spectrum of Atenolol (Fig 1.). IR spectrum of 
Atenolol was characterized by the absorption of-C=O 
group at1651 cm−1&-CONH- group at 1736.73.In spectra 
of Formulation; band was same absorption pattern as that 
of pure drug. Mentioned evidences thus lead to the 
conclusion that changes were not seen as there was no 
physical interaction between the drug and polymers. 
In DSC study also drug was characterized by its melting 
point & formulation was also showing same results as 
drug, by these mentioned evidences lead to the conclusion 
that changes were not seen s there was no physical 
interaction between the drug & polymers (Fig 2).
 
 
Figure 1a: IR Spectrogram of Atenolol Drug & formulation 
 
Figure 1b: DSC of Atenolol Drug & formulation 
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Preparation of core tablets 
Drug-Cyclodextrine complex was prepared to increase the 
solubility & bioavailability. To improve the dissolution 
process of immediate release core, different diluents used 
were spray dried lactose, spray dried mucilage 
lactose,alone and along with superdisinterants(cross 
caramellose sodium, crospovidone, sodium starch 
glycolate). Spray dried lactose was used as filler; binder 
but spray dried mucilage lactose had a property of binding 
as well as disintegrating. But by result that we obtained it 
shows that spray dried lactose with superdisintegrant 
shows good disintegration & dissolution properties. Spray 
dried lactose is highly water soluble & along with 
superdisintegrant the release was very fast. Whereas in 
spray dried mucilage-lactose, might have increased the 
viscosity & might have acted as barrier for diffusion & 
faster dissolution. 
Precompression Parameters of Core Tablet Powder 
Blend  
The results of bulk density, tapped density and 
compressibility index are shown in Table 4. The powder 
blends indicated good flowability with the angle of repose 
values ranging from 29 to 35° according to fixed funnel 
method.. The result of compressibility index was between 
12 to 17, which indicates good to fair flow properties& for 
Hausners ratio was near/less about 1.2, which indicates 
free flowing powder. 
Characterization of Core Tablets   
The tablet hardness, friability, weight variation of all tablet 
formulations were found to be satisfactory and 
reproducible as observed from the data in Table 4. The 
hardness of all the tablets was between 3to5kg/cm
2
.  In the 
present study, the loss in total weight in friability test was 
in the range of 0.77 to 0.91% that indicates,the percentage 
friability for allthe  formulations  was  found  below  1%  
indicating  that  friability  (%)  is  within  the  
acceptablelimits. In a weight variation test, the 
pharmacopoeia limit for the percentage deviation for 
tablets weighing more than 80 mg is ±7.5%.  The  average  
percentage  deviation  of  all  tabletformulations was  
found to be within limit, and hence all formulations passed 
the test foruniformity  of  weight  as  per  official  
requirement. F2 formulation shows good characteristic 
properties compared to other formulations. F2  formulation 
gives90% drug release  in 30 min. F2 formulation was 
selected by possessing good characteristics.
 
Table 4: Pre and post -compression parameter of core tablet 
 
Preparation of press-coated tablets 
Press coated tablets were prepared by using 3 independent 
variables as different concentrations of polymers  by using 
2
3 
factorial design. In press coating polymers used were 
Polyox WSR301, Lubritab, Xanthan gum &Dicalcium 
phosphate. Extremely fast hydration and gel forming 
property of polymer Polyox WSR301 results into decrease 
in drug release with increase in polymer concentration. 
Lubritab was a hydrogenated vegetable oil, which was 
hydrophobic in nature with good binding property played a 
role in controlled release of the formulation. Xanthan gum, 
a polysaccharide-based natural gum, has been widely 
employed as a hydrophilic polymer to prepare controlled 
release matrices because of its cost effectiveness and 
regulatory acceptance. It has been used as a release 
retardant polymer.The use of higher proportions of 
xanthan gum resulted in the formation of a thick polymeric 
gel layer, which acted as a barrier to drug 
diffusion. Dicalcium phosphate may be a simpler, cheaper, 
and a viable way to formulating directly compressible 
sustained release formulations due to its water insoluble 
nature. 
Data fitting to the model 
Pre-compression parameter for powder blend of core tablet 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 
Bulk Density(g/cm3) 0.526 0.55 0.55 0.55 0.55 0.526 0.55 0.526 
Tapped Density(g/cm3) 0.625 0.625 0.666 0.666 0.625 0.625 0.666 0.625 
Angle of Repose(θ ) 34.13 29.24 33.87 32.11 34.45 33.58 31.19 33.74 
Carrs index (%) 15.84 12 17.41 17.41 12 15.84 17.41 15.84 
Hausners ratio (HR) 1.18 1.13 1.21 1.21 1.13 1.18 1.21 1.18 
Post-compression parameters for core tablets 
HARDNESS (Kg/cm2) 
(n=3) 
3.5±0.50 3±0.50 4± 0.50 5±0.50 3.5± 0.00 3±0.50 5± 0.00 5± 0.00 
THICKNESS(mm) 
(n=3) 
2.67±0.00
5 
2.52±0.01
4 
2.58±0.016 2.55±0.00
7 
2.64±0.01
8 
2.54±0.01
6 
2.67±0.01
8 
2.64±0.01
4 
DIAMETER(mm) 6.01±0.00
7 
6.00±0.01
5 
6.00±0.008 6.02±0.01
6 
6.01±0.01
1 
6.01±0.00
3 
6.01±0.01
1 
6.01±0.00
8 
Weight Variation 
(%) (n=20) 
101±0.79 100±0.57 101±0.83 99±1.36 99±0.87 101±0.68 101±0.72 100±0.48 
DISINTEGRATION 
TIME (MIN.) 
8.25 7.15 8.55 16 8.10 15 16 24 
% RELEASE IN 30 
MIN. 
53.59 95.8 51.37 59.16 61.61 52.00 36.72 38.31 
FRIABILITY(%)(n=10) 0.78 0.87 0.81 0.91 0.77 0.82 0.67 0.84 
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A three-factor, two-level optimal design as the response 
surface methodology (RSM) provides 8 runs. All the 
responses observed for 8 formulations were fitted to main 
effect model when using Design Expert (State ease – Ver. 
8.0.7.1) and the values of R
2
 and standard deviation are 
given in Table 7 along with the regression equation 
generated for each response. Only statistically significant 
(p < 0.05) coefficients are included in the equations.
 
 
Figure 2: % Drug Release of core tablets 
Table 5: Summary of Results of Regression Analysis for Response Y1 
 
In the following graphs (Fig 4&5), as the amount of Xanthan gum, Ratio of polox:lubritab & Dicalcium phosphate 
increases lag time also increases. 
 
Figure 3: Effect of Xanthan gum & ratio of Polyox WSR301: Lubritab on lag time 
Response Models F value Prob > F R
2 
Adjusted R
2
 Predicted R
2 
S.D. Remarks 
Y1(Lag time) Main effect 
 
261.53 0.0001 0.9949 0.9911 0.9797 3.95 Suggested 
 
Equation:Y1=175.63+5.62X1+36.88X2-11.88X3 
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Figure 4 Effect of Dicalciumphosphate(DCP) & ratio 
of Polyox WSR301:Lubritab on lag time 
Lag time is the important criteria to deliver drug. In 
following formulations different polymers in different 
concentration were used. In this F7 formulation which 
contains Xanthan gum 100mg, Ratio of polox:lubritab 
125:75mg & Dicalcium phosphate 50mg  shows good lag 
time of about 4 hrs.     
Characterization of press-coated Tablets 
The tablet hardness, friability, weight variation of all 
tablet formulations were found to be satisfactory and 
reproducible as observed from the data in Table 6. The 
hardness of all the tablets was between7 and 8kg/cm
2
.  In 
the present study, the loss in total weight in friability test 
was in the range of 0.68 to 0.92% that indicates,the 
percentage friability for allthe  formulations  was  found  
below  1%  indicating  that  friability  (%)  is  within  the  
acceptablelimits. In a weight variation test, the 
pharmacopoeia limit for the percentage deviation for 
tablets weighing more than250mg is  ±5%.  The  average  
percentage  deviation  of  all  tabletformulations was  
found to be within limit, and hence all formulations 
passed the test foruniformity  of  weight  as  per  official  
requirement. In case of press coated tablets formulations 
were characterised & optimised by 2
3
 factorial design & 
formulation F7 shows good lag time of 3.5 hrs.
 
Table 6: Post-compression parameters for press-coated tablets 
 
 
Figure 5: % Drug Release of coated formulations 
CONCLUSION 
Optimization of press-coated pulsatile tablet for atenolol 
was carried out usinga three-factor, two-level, full factorial 
design. This allowedrapid evaluation and identification of 
the parameters importantin determining the desired 
responses, ie, the lag timefor atenolol release.The present 
study demonstrates that theAtenolol compression coated 
tablet could be successfullydeliverdrug in right time, right 
place. It was better formulation compared to conventional  
tablet. So it is also a patient compliant. It was concluded 
that Formulation F2 was good formulation as it was 
meeting all specifications for post compression 
characteristic & by the factorial model. 
 
 F1 F2 F3 F4 F5 F6 F7 F8 
HARDNESS 
(Kg/cm2)(n=3) 
7±0.40 7.5±0.27 7±0.63 7±0.28 8±0.29 7.5±0.13 8±0.45 7±0.50 
THICKNESS 
(mm)(n=3) 
6.02±0.15 6.13±0.17 5.95±0.26 5.97±0.15 6.09±0.27 5.93±0.26 5.89±0.15 6.17±0.027 
DIAMETER 
(mm)(n=3) 
10±0.01 10±0.002 10±0.02 10±0.01 10±0.02 10±0.02 10±0.02 10±0.01 
WEIGHT 
VARIATION 
(%)(n=20) 
400±1.29 351±1.13 300±1.24 350±0.87 402±0.73 400±1.17 451±0.63 350±0.82 
FRIABILITY 
(%)(n=10) 
0.88 0.93 0.68 0.73 0.77 0.73 0.86 0.92 
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